Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A family therapy could curb early psychosis risk in youth

NCT ID NCT07743645

Prevention Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study tests whether a 16-week family-based psychosocial intervention can reduce persistent and distressing psychotic-like experiences in children and young adults who have a family history of schizophrenia spectrum disorders (SSD). Participants and their caregivers will attend weekly sessions to address their top modifiable risk factors. The trial compares outcomes in those with high versus low baseline brain patterns associated with SSD, using questionnaires and cognitive tests to measure changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A 16-week family-based psychosocial intervention targeting modifiable risk factors for schizophrenia spectrum disorders
What this could lead to
If effective, this approach could offer a way to reduce distressing psychotic-like experiences and potentially lower the risk of developing schizophrenia in high-risk youth.
What could go wrong
This is an early-stage trial with a modest size, and the outcome relies on self-reported symptoms. The intervention may not produce lasting benefits or may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 19 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and/or parent/legal guardian report and confirmed by a structured interview * screening positive for two or more risk factors targeted by the intervention * Participants and parent(s)/legal guardian(s) agree to participate * psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks. Exclusion Criteria: * Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview * Current or past antipsychotic medication use to specifically treat a psychotic disorder * major medical and neurological conditions * moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments; * current drug or alcohol use that impacts functioning and study engagement; * Not able to give assent, permission, or consent. * Not able to undergo MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Family history of schizophrenia spectrum disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Family history of schizophrenia spectrum disorder Prevention Risk factors for mental illness

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.